(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 17 March 2005 (17.03.2005)

PCT

(10) International Publication Number $WO\ 2005/023820\ A1$

(51) International Patent Classification⁷: C07D 498/04

(21) International Application Number:

PCT/DK2004/000579

(22) International Filing Date:

1 September 2004 (01.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA200301277 5 September 2003 (05.09.2003) DK 60/500,422 5 September 2003 (05.09.2003) US

(71) Applicant (for all designated States except US): H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, DK-2500 Valby-Copenhagen (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PETERSEN, Hans [DK/DK]; Guldagervej 11, DK-2720 Vanløse (DK). BECH SOMMER, Michael [DK/DK]; Regattavej 6, DK-2880 Bagsværd (DK). DANCER, Robert [AU/DK]; Sønderkær 53, DK-2650 Hvidovre (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR THE MANUFACTURE OF THIP



(57) Abstract: The present invention relates to a new method of preparing gaboxadol (THIP), which is useful for treating sleep disorders. In particular a method of preparing THIP comprising reacting a compound of formula (8b) or a salt thereof with an acid, typically a mineral acid, to obtain THIP as an acid addition salt. The present invention also relates to several intermediates.

Method for manufacture of THIP

Field of the invention

The present invention relates to a new method of manufacturing the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c9]pyridin-3-ol (THIP) having the INN name Gaboxadole, and also to new intermediates, such as isoxazolo[5,4-c]pyridin-3-ol (HIP), used in the method.

Background of the invention

Receptors for the major inhibitory neurotransmitter, gammaamino butyric acid (GABA), are divided into two main classes: GABA_A receptors which are members of the ligand gated ion channel superfamily; and the GABA_B receptors which are G-protein coupled receptors.

In a number of clinical conditions, hypoactivity of the inhibitory GABA system has been hypothesised as the underlying mechanism of the pathology in question. These conditions include epilepsy, anxiety, stress, sleep disorders and pain. However, although positive modulators of the GABA_A receptor complex, such as benzodiazepines, in a number of circumstances are very effective, there is a general consensus that unselective benzodiazepines produce so many side effects that compounds substituting for presently used drugs are needed (Costa and Guidotto *Trends Pharmacol. Sci.*1996, 17, 192-200).

20

25

30

5

10

15

The present invention provides non-steroidal and non-benzodiazepine compounds interacting directly with the recognition site at the GABA_A receptor as agonists, which have beneficial effects in disease states relating to reduced neurostoroidal activation.

The diseases, including premenstrual syndrome, postnatal depression and post menopausal related dysphoric disorders, are significantly better treated with GABA_A agonists than with benzodiazepines and neurosteroids which produce tolerance after short term treatment.

The potent GABA agonist 4,5,6,7-tetrahydroisoxazolo[5,4-c9]pyridin-3-ol (THIP) is disclosed in EP 000 338 B1 wherein a method of making the compound is also described. THIP is useful for treating sleep disorders which is disclosed in EP 840601 B1.

Definitions

The term "a" as used herein is intended to mean "one or more" or "at least one", except where it is clear from the text that it means one.

35

The term " C_{1-4} alkyl", " C_{1-6} alkyl", or " C_{1-12} alkyl" as used herein refers to a branched or unbranched alkyl group having from one to four, one to six, or one to twelve carbon atoms

inclusive, respectively, including but not limited to methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl.

The term " C_{1-6} alkoxy", or " C_{1-12} alkoxy" as used herein designate such groups in which the C_{1-6} -alkyl or C_{1-12} -alkyl is as defined above and is linked *via* an oxygen, including but not limited to methoxy, ethoxy, 1-propoxy, 1-butoxy.

The term " C_{2-6} alkenyl", or " C_{2-12} alkenyl" as used herein, respectively, designate such groups having from two to six carbon atoms, or two to twelve carbon atoms, including one double bond respectively, including but not limited to ethenyl, propenyl, and butenyl.

The term "C₁₋₆alkylene" as used herein refers to a branched or unbranched alkylene group having from one to six carbon atoms inclusive, including but not limited to methylene, and ethylene.

15

10

The term "C₃₋₈cycloalkyl" as used herein designates a monocyclic or bicyclic carbocycle having three to eight carbon atoms inclusive, including but not limited to cyclopropyl, cyclopentyl, and cyclohexyl.

The term "C₃₋₈cycloalkenyl" as used herein designates a monocyclic or bicyclic carbocycle having three to eight carbon atoms inclusive and including one double bond.

The term " C_{1-12} alkyl chloroformate" designate such groups in which the C_{1-12} -alkyl, such as C_{1-6} -alkyl, is as defined above and is the ester portion of a chloroformate, including but not limited to methyl chloroformate or ethyl chloroformate.

The term "acyl" as used herein refers to formyl, C_{1-6} -alk(en/yn)ylcarbonyl, arylcarbonyl, arylcarbonyl, C_{1-6} -alk(en/yn)ylcarbonyl, C_{3-8} -cycloalk(en)ylcarbonyl or a C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl-carbonyl group.

30

25

The expression C_{1-6} -alk(en/yn)yl means a C_{1-6} -alkyl, C_{2-6} -alkenyl or a C_{2-6} -alkynyl group. The expression C_{3-8} -cycloalk(en)yl means a C_{3-8} -cycloalkyl- or cycloalkenyl group.

The term "aryl" as used herein refers to carbocyclic, aromatic systems such as phenyl and naphtyl.

"heteroaryl" as used herein refers to 5- to 6- membered aromatic systems containing 1 to 5 carbon atoms and one or more heteroatoms selected from O, S or N, such as 5-membered monocyclic rings such as oxathiazoles, dioxazoles, dithiazoles, oxadiazoles, thiadiazoles, triazoles, isoxazoles, oxazoles, isothiazoles, thiazoles, imidazoles, pyrazoles, pyrroles, furan(s) or thiophene(s), e.g. 3H-1,2,3-oxathiazole, 1,3,2-oxathiazole, 1,3,2dioxazole, 3H-1,2,3-dithiazole, 1,3,2-dithiazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1H-1,2,3-triazole, isoxazole, oxazole, isothiazole, thiazole, 1H-imidazole, 1H-pyrazole, 1Hpyrrole, furan or thiophene, or 6-membered monocyclic rings such as oxathiazines, dioxazines, dithiazines, oxadiazines, thiadiazines, triazines, oxazines, thiazines, pyrazines, pyridazines, pyrimidines, oxathiins, dioxins, dithiins, pyridines, pyrans or thiins, e.g. 1,2,3oxathiazine, 1,2,4-oxathiazine, 1,2,5-oxathiazine, 1,4,2-oxathiazine, 1,4,3-oxathiazine, 1,2,3dioxazine, 1,2,4-dioxazine, 4H-1,3,2-dioxazine, 1,4,2-dioxazine, 2H-1,5,2-dioxazine, 1,2,3dithiazine, 1,2,4-dithiazine, 4H-1,3,2-dithiazine, 1,4,2-dithiazine, 2H-1,5,2-dithiazine, 2H-1,2,3-oxadiazine, 2H-1,2,4-oxadiazine, 2H-1,2,5-oxadiazine, 2H-1,2,6-oxadiazine, 2H-1,3,4oxadiazine, 2H-1,2,3-thiadiazine, 2H-1,2,4-thiadiazine, 2H-1,2,5-thiadiazine, 2H-1,2,6thiadiazine, 2H-1,3,4-thiadiazine, 1,2,3-triazine, 1,2,4-triazine, 2H-1,2-oxazine, 2H-1,3oxazine, 2H-1,4-oxazine, 2H-1,2-thiazine, 2H-1,3-thiazine, 2H-1,4-thiazine, pyrazine, pyridazine, pyrimidine, 4H-1,3-oxathiin, 1,4-oxathiin, 4H-1,3-dioxin, 1,4-dioxin, 4H-1,3dithiin, 1,4-dithiin, pyridine, 2*H*-pyran or 2*H*-thiin.

20

30

35

5

10

15

The term "acidification" as used herein means that an acid is added to the reaction mixture adjusting the pH to below pH 6.5.

The term "a leaving group" as used herein is a well-known expression to the skilled chemist, examples being halogens, such as Br, Cl, I, or mesylate or tosylate.

The term "a salt" as used herein is intended to mean any salt which a particular compound may form, and is usually intended to comprise acid addition salts, however, the compounds may also form other salts with bases, such as metal salts, eg. sodium salts, and ammonium salts, eg. salts of amines, such as triethylamine.

The term "an acid addition salt" as used herein is intended to mean any acid addition salt which a particular compound may form upon reaction of the compound with the acid in a solvent, as known to the skilled person in the art. Suitable examples are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like. Other suitable examples are organic salts such as acetic, propionic, glycolic, oxalic, malonic, succinic, citric acid and the like.

The term "a mild reducing agent" as used herein is a well-known expression to the skilled chemist, reference is made to Brown, H. C; Krishnamurthy; *Tetrahedron*, 35, 1979, pp 567-607. Suitable examples are borohydrides.

The term "a nucleophile" as used herein is a well-known expression to the skilled chemist, reference is made to "Advanced Organic Chemistry" (3rd edition), Jerry March, Wiley-Interscience. The term "a soft nucleophile" as used herein is also described in "Advanced Organic Chemistry" (3rd edition), Jerry March, Wiley-Interscience. Suitable examples are Cl⁻, Br⁻, I⁻, or NC-S⁻.

10

The term "a dehydrating agent" as used herein is a well-known expression to the skilled chemist, and is intended to cover agents, such as thionylchloride, a chloroformate such as isobutyl chloroformate, or a carbodiimide such as DCI/DCC.

15 Description of the invention

WO 2005/023820

The present invention relates to a new method of manufacturing the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c9]pyridin-3-ol (THIP).

In one aspect the present invention relates to a method of preparing THIP comprising the steps:

a) reacting a compound of formula (2)

with an alkylating agent of formula (3)

$$\begin{array}{c}
R^3 \\
R^2 - C - L \\
H
\end{array}$$
(3)

25

wherein R^2 and R^3 are independently selected from H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, acyl, aryl, or heteroaryl, optionally substituted with a C_{1-12} alkyl, C_{1-12} alkoxy, or aryl; and

30 L is a leaving group,

to obtain a quarternary salt of formula (4)

HO
$$\begin{array}{c}
N \\
N \\
CH \\
R^2 \\
R^3
\end{array}$$
(4)

wherein L, R² and R³ are as defined above,

b) reacting the quarternary salt of (4) with a mild reducing agent to obtain a compound of formula (5)

HO
$$N$$
 N
 CH
 R^2
 R^3
 R
 (5)

wherein R² and R³ are as defined above,

c) reacting a compound of formula (5) with a reagent of formula (6a)

wherein R' is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

X is a leaving group,

Y is O or S,

5

10

Z is O, S or C₁₋₆alkyl,

optionally followed by reaction with a nucleophile,

15 to obtain a mixture of a compound of formula (7a) and a compound of (7b)

wherein Y, Z, and R' are as defined above,

d) reacting the mixture of (7a) and (7b) with a nucleophile, followed by acidification, to obtain a compound of formula (8a)

wherein Y, Z, and R' are as defined above,

e) reacting a compound of formula (8a)

5 with an acid to obtain THIP as an acid addition salt.

In a further aspect the present invention relates to a method of preparing THIP wherein steps a and b are as above, comprising the further steps:

c2) reacting a compound of formula (5) with a reagent of formula (6b)

$$10 \quad RU = W$$
 (6b)

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U is N or CR¹, wherein R¹ is H, or R,

W is O, S or NR⁴, wherein R⁴ is H, or R,

optionally followed by reaction with a nucleophile, to obtain a mixture of a compound of formula (7c) and a compound of (7d)

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U' is NH or CHR¹, wherein R¹ is H, or R, W is O, S or NR⁴, wherein R⁴ is H, or R,

d2) reacting the mixture of (7c) and (7d) with a nucleophile, followed by acidification, to obtain a compound of formula (8b)

wherein W, U', and R are as defined above,

e2) reacting a compound of formula (8b) with an acid to obtain THIP as an acid addition salt.

5

The compound of formula (2)

is novel and may be prepared by the steps comprising:

i) reacting a compound of formula (9)

10

wherein R'' is C₁₋₄alkyl (such as methyl, ethyl, n-propyl, n-butyl), with hydroxylamine hydrochloride and a base, such as NaOH, to obtain a compound of formula (10)

15

and ii) reacting the compound of formula (10) with a dehydrating agent to obtain (2). The base should be strong enough to adjust $pH \ge 9$, preferably ≥ 10 .

20

Typical compounds of formula (9) are methyl and ethyl 3-hydroxy-isonicotinate, which are described in (Contribution No. 240 from the research laboratories of Hoffmann-La Roche Inc.), Synthetic Tuberculostats. II, pages 547-554, by H. Herbert Fox. The compound 3,*N*-

dihydroxy-isonicotinamide (10) is described in Ceskoslov. Farm. 11, 1962, pages 76-79, and in Acta Facultatis Pharmaceuticae Bohemoslovenicae TOM. IV. 1962, pages 65-91.

8

In a further aspect the present invention relates to a method of preparing the compound of formula (2) comprising reacting the compound of formula (10)

10

20

25

30

with a dehydrating agent to obtain (2). In an embodiment the dehydrating agent is selected from thionylchloride, a chloroformate, or a carbodiimide. Typical dehydrating agents are thionylchloride, isobutyl chloroformate, and DCI/DCC.

Accordingly, the present invention also relates to a compound of formula (2)

or a salt thereof. In one embodiment the salt is an acid addition salt, such as a hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or phosphoric acid salt. In another embodiment it is the free base.

In step a of the present method the reaction is typically carried out in an organic solvent. In one embodiment step a is carried out in a polar solvent, such as NMP.

In the alkylating agent of formula (3) R^2 and R^3 are independently selected from H, C_{1-12} alkyl, C_{1-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, aryl, or heteroaryl, optionally substituted with a C_{1-12} alkyl, C_{1-12} alkoxy, or aryl, and L is a leaving group, eg. Br, Cl, I, OMs, or OTs. When R^2 and R^3 are independently selected from C_{1-12} alkyl, C_{1-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, aryl, or heteroaryl, each of these substituents may optionally be substituted with a C_{1-12} alkyl, C_{1-12} alkoxy, or aryl. In a further embodiment one of R^2 and R^3 is H and the other is as above. Typically, R^2 and R^3 are independently selected from H, methyl, ethyl, allyl, phenacyl, phenyl or methoxyphenyl. Typically, L is selected from Br, Cl, I, OMs, or OTs. Examples of alkylating agents are selected from MeI, EtI, BzBr, p-CH₃OC₆H₄CH₂Br, allylBr, and the corresponding mesylates (OMs) and tosylates (OTs).

In step b of the present method the reaction is carried out in an organic or inorganic solvent, or mixtures thereof. In one embodiment step b is carried out in alcohol and water, such as aqueous ethanol.

9

Typically, the mild reducing agent in step b is selected from LiBH₄ or NaBH₄.

5

In step c one alternative is to react a compound of formula (5) with a reagent of formula (6a)

wherein R' is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl or heteroaryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

10 X is a leaving group,

Y is O or S, and

Z is O, S or C_{1-6} alkyl. When Z is C_{1-6} alkyl it may be necessary to further react with a nucleophile such as Cl^- , Br^- , l^- , or NC-S $^-$. In one embodiment R $^+$ is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or phenyl optionally substituted with a C_{1-6} alkyl, C_{1-6} alk

15 6alkoxy, or phenyl,

X is selected from Cl, Br, I,

Y is O, and

25

Z is O. In particular, the reagent of formula (6a) is selected from C_{1-12} alkyl chloroformate, or C_{1-12} alkyl chlorothiolformate, typically, C_{1-6} alkyl chloroformate, such as methyl chloroformate, ethyl chloroformate, or C_{1-6} alkyl chlorothiolformate, such as ethyl chlorothiolformate.

Another alternative in step c is to first protect a compound of formula (5) as a carbonate or carbamate, such as a *t*-butyl- or 2,2,2-trichloroethylcarbonate/carbamate, and then reacted with the reagent of formula (6a), to obtain a mixture of a compound of formula (7a) and a compound of formula (7b).

In step c2 one alternative is to react a compound of formula (5) with a reagent of formula (6b)

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U is N or CR¹, wherein R¹ is H, or R,

W is O, S or NR⁴, wherein R⁴ is H, or R,

optionally followed by reaction of a nucleophile such as Cl, Br, I, or NC-S,

to obtain a mixture of a compound of formula (7c) and a compound of formula (7d)

wherein U', W, and R are as defined above. In one embodiment R is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or phenyl optionally substituted with a C_{1-6} alkyl, C_{1-6} alkoxy, or phenyl,

U' is NH or CHR¹, wherein R¹ is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, acyl, or phenyl optionally substituted with a C₁₋₆alkyl, C₁₋₆alkoxy, or phenyl, W is O, S or NR⁴, wherein R⁴ is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, acyl, or phenyl optionally substituted with a C₁₋₆alkyl, C₁₋₆alkoxy, or phenyl, and the nucleophile is selected from Cl⁻, Br⁻, I', or NC-S⁻. In particular, the reagent of formula (6b) is selected from an isocyanate such as isopropyl isocyanate or phenyl isocyanate, or an isothiocyanate such as phenyl isothiocyanate, or a ketene.

In step d the mixture of (7a) and (7b) is reacted with a nucleophile, typically a soft nucleophile, followed by acidification, to obtain a compound of formula (8a)

15

20

wherein Y, Z, and R' are as defined above. In one embodiment the soft nucleophile is ammonia, an amine, a diamine, a thiol, a thiolate, a sulfide in a solvent, such as an aqueous or organic solution. Examples of soft nucleophiles are aqueous ammonia, methylamine, and ethylenediamine. The step of acidification may be performed with an aqueous acid adjusting the pH to \leq 5. In further embodiments acidification is performed by adjusting the pH to \leq 4, typically \leq 3, such as \leq 2, eg. pH is about 1. Typically, the aqueous acid is a mineral acid, such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or phosphoric acid.

As mentioned above in step d, the nucleophile is in an aqueous or organic solution.

Preferably, after reaction with the nucleophile the aqueous phase is separated, followed by acidification as outlined above, and extraction into an organic phase, eg. ethyl acetate. This

purification step provides a compound of formula (8a) or a salt thereof in very high purity, typically, more than 98%, such as greater than 99% according to HPLC (such as the Analytical Method HPLC as described below).

11

PCT/DK2004/000579

In step d2 the mixture of (7c) and (7d) is reacted with a nucleophile, typically a soft nucleophile, followed by acidification, to obtain a compound of formula (8b)

20

WO 2005/023820

wherein U', W, and R are as defined above. In one embodiment the soft nucleophile is
ammonia, an amine, a diamine, a thiol, a thiolate, a sulfide in a solvent, such as an aqueous or
organic solution. Examples of soft nucleophiles are aqueous ammonia, methylamine, and
ethylenediamine. The step of acidification may be performed with an aqueous acid adjusting
the pH to ≤5. In further embodiments acidification is performed by adjusting the pH to≤4,
typically ≤3, such as ≤2, eg. pH is about 1. Typically, the aqueous acid is a mineral acid, such
as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or phosphoric acid.

As mentioned above in step d (or d2), the nucleophile is in an aqueous or organic solution. Preferably, after reaction with the nucleophile the aqueous phase is separated, followed by acidification as outlined above, and extraction into an organic phase, eg. ethyl acetate. This purification step provides a compound of formula (8a) (or (8b)) or a salt thereof in very high purity, typically, more than 98%, such as greater than 99% according to HPLC (such as the Analytical Method HPLC as described below).

In step e (or e2) a compound of formula (8a) (or (8b)) or a salt thereof is reacted with an acid, typically a mineral acid, to obtain THIP as an acid addition salt. The reaction is typically carried out in an organic solvent, such as an organic carboxylic acid, eg. acetic acid. Examples of suitable mineral acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or phosphoric acid.

Accordingly, a further aspect of the present invention relates to a method of preparing THIP comprising reacting a compound of formula (8a) or a salt thereof

wherein R' is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

Y is O or S, and

5 Z is O, S or C_{1-6} alkyl,

10

15

25

with an acid, typically a mineral acid, to obtain THIP as an acid addition salt. The reaction is typically carried out in an organic solvent, such as an organic carboxylic acid, eg. acetic acid. Examples of suitable mineral acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or phosphoric acid.

Since a compound of formula (8a) is a useful intermediate in the preparation of THIP, it is a further aspect of the present invention.

Thus, the present invention relates to compound of formula (8a)

wherein R' is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

Z is O, S or C_{1-6} alkyl, or

Y is O or S,

a salt thereof. In one embodiment R' is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3} . $_{8}$ cycloalkenyl, acyl, or phenyl optionally substituted with a C_{1-6} alkyl, C_{1-6} alkoxy, or phenyl. In another embodiment Y is O. In another embodiment Z is O. In a further embodiment Y and Z are both O, and R' is selected from any one of the above substituents such as C_{1-6} alkyl, or benzyl.

Furthermore, a further aspect of the present invention relates to a method of preparing THIP comprising reacting a compound of formula (8b) or a salt thereof

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

13

U' is NH or CHR¹, wherein R¹ is H, C₁-6alkyl, C₂-6alkenyl, C₃-8cycloalkyl, C₃-8cycloalkenyl,

acyl, or phenyl optionally substituted with a C₁-6alkyl, C₁-6alkoxy, or phenyl,
W is O, S or NR⁴, wherein R⁴ is H, C₁-6alkyl, C₂-6alkenyl, C₃-8cycloalkyl, C₃-8cycloalkenyl,
acyl, or phenyl optionally substituted with a C₁-6alkyl, C₁-6alkoxy, or phenyl,
with an acid, typically a mineral acid, to obtain THIP as an acid addition salt. The reaction is
typically carried out in an organic solvent, such as an organic carboxylic acid. Examples of
suitable mineral acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or
phosphoric acid.

Since a compound of formula (8b) is a useful intermediate in the preparation of THIP, it is a further aspect of the present invention.

15

Thus, the present invention relates to compound of formula (8b)

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U' is NH or CHR¹, wherein R¹ is H, C₁-6alkyl, C₂-6alkenyl, C₃-8cycloalkyl, C₃-8cycloalkenyl, acyl, or phenyl optionally substituted with a C₁-6alkyl, C₁-6alkoxy, or phenyl, W is O, S or NR⁴, wherein R⁴ is H, C₁-6alkyl, C₂-6alkenyl, C₃-8cycloalkyl, C₃-8cycloalkenyl, acyl, or phenyl optionally substituted with a C₁-6alkyl, C₁-6alkoxy, or phenyl, or a salt thereof. In one embodiment R is C₁-6alkyl, C₂-6alkenyl, C₃-8cycloalkyl, C₃-8cycloalkenyl, acyl, or phenyl optionally substituted with a C₁-6alkyl, C₁-6alkoxy, or phenyl. In another embodiment W is O or S. In a further embodiment W is NR⁴, wherein R⁴ is H, C₁-6alkyl, C₂-6alkenyl, C₃-8cycloalkyl, C₃-8cycloalkenyl, acyl, or phenyl optionally substituted with a C₁-6alkyl, C₁-6alkoxy, or phenyl. In a further embodiment U' is NH.

Experimental part

The following examples are meant to illustrate various embodiments of the invention and should not be read as limiting the scope of protection.

5 Overview of the HIP to THIP process

Analytical Method HPLC

HPLC analyses are performed according to the procedures described below.

Instrument Varian ProStar System	Pump Model 230				
	Detector UV Model 310				
	Autosampler/Column Oven Model 410				
	Star Chromatography Workstation				
	Software V. 5.5				
Detector	UV 220 nm				
Column	Merck LiChrosorb RP8 250x4 mm, 5 μm				
Column Temperature	35 °C				
Mobile Phase	Water/Acetonitrile 50:50; buffered to				
	pH=3 using H ₃ PO ₄ /NEt ₃				
Flow	1.0 mL/min				
Volume injected	10 μl				
Run time	10 min				
Gradient	No Gradient; Isocratic				

5 Standard Preparation

To a small sample (0.1 < mg < 1.0) was added ca. 1.2 mL mobile phase, and the sample was shaken until dissolution was complete.

Analytical Procedure

The sample was injected, and the area of the desired peak was measured, as was the total area. The product assay was calculated with the formula:

Assay% = Sample Area/Total Area.

In example A below is described a method of preparing the intermediate isoxazolo[5,4-c]pyridin-3-ol (HIP)

16

Example A

3,N-Dihydroxy-isonicotinamide

To a stirred suspension of methyl 3-hydroxy-isonicotinate (176 g; 1.15 mol) in water/ice (50/50, 1700 mL), was added hydroxylamine hydrochloride (127.9 g; 1.84 mol). The temperature fell to -5 °C and then aqueous NaOH solution (454 mL, 28% w/v) was added dropwise keeping the temperature below 5 °C during the addition. Hereafter the reaction mixture was stirred at ambient temperature for 1.5 h followed by heating to 60 °C. At this temperature the pH was adjusted to 5.4 by the addition of aqueous hydrochloric acid (10 M) at which point a heavy precipitate forms. The reaction mixture was then stirred at ambient temperature followed by cooling to 5 °C. The pH was then adjusted to 4.0 by the addition of aqueous hydrochloric acid (10 M), and then was stirred whilst cold for 1,5 h. The crystals were filtered off, rinsed with water (3 x 100 mL), dried on the filter and then dried further at reduced pressure and 40 °C overnight to give 3,N-dihydroxy-isonicotinamide (169.3 g, 96%; HPLC purity 98%) as a white solid.

NMR data: 1 H-NMR (DMSO-d6, 250 MHz) $\delta = 7.55$ (1H, d, J=6 Hz); 8.11 (1H, d, J=6 Hz); 8.32 (1H, s); 9.56 (1H, s, broad peak); 11.50 (1H, s, broad peak) ppm.

Isoxazolo[5,4-c]pyridin-3-ol (HIP)

25 Method A

20

To a stirred suspension of 3,N-dihydroxy-isonicotinamide (50 g; 0.32 mol) in DMF (300 mL), cooled on a water bath at ambient temperature, was added carbonyldiimidazole (DCI) (66.4 g; 0.41 mol. The reaction was stirred over night at ambient temperature.

The next day the solvent was removed under reduced pressure at 70 °C and the residue was dissolved in water and cooled on ice. The pH of the solution (≅ 7.5) was adjusted to 4.5 by the addition of an aqueous solution of hydrochloric acid (ca. 65 mL, 10 M). The desired product crystallised heavily from the solution. The slurry was evaporated to ca. 2/3 volume to remove traces of DMF, cooled on ice for a couple of hours and filtered. The crystals so obtained were rinsed twice with water and twice with ethanol and dried under reduced pressure at 60 °C overnight to give isoxazolo[5,4-c]pyridin-3-ol (41.7 g, 96 %; HPLC purity >99 %) as a white solid.

NMR data: 1 H-NMR (DMSO-d6, 250 MHz) $\delta = 7.84$ (1H, d, J=6 Hz), 8.53 (1H, d, J=6 Hz), 9.08 (1H, s) ppm.

Method B

10

15

20

25

A suspension of 3,*N*-dihydroxy-isonicotinamide (168 g; 1.09 mol) in pyridine (1600 mL) that had been vigorously stirred for 15 min. to ensure an even suspension, was cooled on an icebath to 5 °C. Thionylchloride (241 g; 2.03 mol) was added dropwise over 1 hour whilst maintaining the temperature below 10 °C and the reaction was checked for unreacted starting material by means of the hydroxamic acid test (5 % FeCl₃ in 1M HCl was added to a reaction sample in ethanol, a magenta colour was produced if hydroxamic acid was present). After the addition was complete the cooling bath was removed and the reaction was allowed to warm up to ambient temperature over 1 hour. The reaction mixture was poured into 2 kg of ice/water with vigorous stirring and the pH was adjusted to 3 with concentrated aqueous hydrochloric acid (*ca.* 1.1 L, 10 M). The title compound crystallized out and the mixture was stirred on an ice-bath for 2 hours. The mixture was filtered and the residue was washed with water, ethanol and diethyl ether and dried under reduced pressure at 60 °C overnight to give isoxazolo[5,4-c]pyridin-3-ol (123 g, 83 %; HPLC purity 98 %) as a white solid.

NMR data: ¹H-NMR (DMSO-d6, 250 MHz) δ = 7.84 (1H, d, J=6 Hz), 8.53 (1H, d, J=6 Hz), 9.08 (1H, s) ppm.

18

Example 1

6-Benzyl-3-hydroxy-isoxazolo[5,4-c]pyridin-6-ium bromide

5

To a stirred solution of isoxazolo[5,4-c]pyridin-3-ol (50.0 g, 367 mmol) in NMP (100 ml) was added benzyl bromide (75.4 g, 441 mmol) dropwise rapidly. The thick solution was stirred for 24 h. The mixture was then added slowly to acetone (1.5 L) with stirring, and the solution was seeded. Stirring was continued at room temperature for 30 min, and then for a further 1 h in an ice/water bath. The mixture was filtered, the residue was washed with acetone and then dried under vacuum to give 6-benzyl-3-hydroxy-isoxazolo[5,4-c]pyridin-6-ium bromide (94.1 g, 83%; HPLC: 91% pure) as a white crystalline solid.

NMR data: 1 H-NMR (DMSO-d6, 500 MHz) $\delta = 6.03$ (2H, s), 7.4-7.5 (3H, m), 7.6 (2H, m), 8.54 (1H, d, J=6 Hz), 9.03 (1H, d, J=6 Hz), 10.15 (1H, s) ppm.

15

25

10

Example 2

20 6-Benzyl-4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol

To a stirred solution of 6-benzyl-3-hydroxy-isoxazolo[5,4-c]pyridin-6-ium bromide (93 g, 303 mmol) in ethanol/water (500 mL/500 mL) was added NaBH₄ (18.66 g, 494 mmol) cautiously portionwise, keeping the temperature under 35 °C (caution! Foams on addition!). The mixture was stirred for 24 h. The mixture was filtered, and the residue was washed with

19

water. The combined filtrates were evaporated under reduced pressure until all of the ethanol had evaporated. A solid began to precipitate, and so the mixture was cooled in an ice-water bath with stirring for 30 min. The solution was filtered, and the residue was washed with cold water. The residue was dried to give 6-benzyl-4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol (48.6 g, 70%; HPLC 94% pure) as a yellowish solid. After some further evaporation of the combined mother liquors, a second crop gave a further 10.3 g (HPLC: 97.7% pure). NMR data: 1 H-NMR (DMSO-d6, 500 MHz) δ = 2.3 (2H, t, J=6 Hz), 2.67 (2H, t, J=6 Hz), 3.45 (2H, s), 3.7 (2H, s), 7.2-7.4 (5H, m), 11.3 (1H, bs) ppm.

10 Example 3

5

4,5,6,7-Tetrahydro-isoxazolo[5,4-c]pyridin-3-ol hydrobromide

15 Method A

20

25

30

To a stirred solution of 6-benzyl-4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol (11.5 g, 50 mmol) and DMAP (0.61 g, 5 mmol) in ethyl acetate (100 mL) under a nitrogen atmosphere was added a solution of (Boc)₂O (16.4 g, 75 mmol) in ethyl acetate (20 mL). After 30 min was added DIPEA (4.35 mL, 25 mmol) and methyl chloroformate (7.73 mL, 100 mmol), and the mixture was stirred for 48 h. the mixture was cooled in an ice-water bath, and an aqueous solution of ammonia (25% w/v, 120 mL) was added. After 15 minutes the aqueous phase was separated, and was adjusted to pH 1.0 by the addition of aqueous hydrochloric acid (10 M). This aqueous phase was extracted twice with ethyl acetate, and these ccombined extracts were dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was dissolved in a solution of gaseous HBr in acetic acid (33% w/v, 30 mL), and the mixture was stirred at 40 °C for 6 hours. The mixture was then cooled in an ice-water bath, and ethanol (90 mL) was added. A precipitate formed, and the mixture was stirred in the cold for a further 1 h. The mixture was filtered, and the reside was washed with cold ethanol and dried to give 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol hydrobromide (6.4 g, 58%; HPLC >99% pure) as a white solid.

Method B

5

10

15

20

WO 2005/023820

To a stirred solution of 6-benzyl-4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol (2.3 g, 10 mmol) in ethyl acetate (25 mL) under a nitrogen atmosphere was added DIPEA (2.6 mL, 15 mmol) and methyl chloroformate (2.7 mL, 35 mmol), and the mixture was stirred for 48 h. the mixture was cooled in an ice-water bath, and an aqueous solution of ammonia (25 % w/v, 30 mL) was added. After 15 minutes the aqueous phase was separated, and was adjusted to pH 1.0 by the addition of aqueous hydrochloric acid (10 M). This aqueous phase was extracted twice with ethyl acetate, and these combined extracts were dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was dissolved in a solution of gaseous HBr in acetic acid (33% w/v, 6.3 mL), and the mixture was stirred at 40 °C for 6 hours. The mixture was then cooled in an ice-water bath, and ethanol (25 mL) was added. A precipitate formed, and the mixture was stirred in the cold for a further 1 h. The mixture was filtered, and the reside was washed with cold ethanol and dried to give 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol hydrobromide (1.35 g, 58 %; HPLC >99 % pure) as a white solid. A further crop gave a further 0.15 g, bringing the total yield up to 68 % (HPLC: >99 % pure).

20

PCT/DK2004/000579

NMR data: 1 H-NMR (DMSO-d6, 500 MHz) $\delta = 2.6$ (2H, t, J=6 Hz), 3.35 (2H, t, J=6 Hz), 4.3 (2H, s), 9.5 (*ca.* 2H, bs), *ca.* 11.6 (*ca.* 1H, bs) ppm.

WE CLAIM:

1. A method of preparing THIP comprising the steps:

a) reacting a compound of formula (2)

5

with an alkylating agent of formula (3)

$$R^{2} - \overset{R^{3}}{\overset{}{\overset{}{\text{C}}}} - L$$

$$H$$

$$(3)$$

wherein R^2 and R^3 are independently selected from H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkenyl, acyl, aryl, or heteroaryl, optionally substituted with a C_{1-12} alkyl, C_{1-12} alkyl,

12alkoxy, or aryl, and

L is a leaving group,

to obtain a quarternary salt of formula (4)

15

wherein L, R² and R³ are as defined above,

b) reacting the quarternary salt of (4) with a mild reducing agent to obtain a compound of formula (5)

20

wherein R² and R³ are as defined above,

c) reacting a compound of formula (5) with a reagent of formula (6a)

wherein R' is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

X is a leaving group,

5 Y is O or S,

Z is O, S or C₁₋₆alkyl,

optionally followed by reaction with a nucleophile,

to obtain a mixture of a compound of formula (7a) and a compound of (7b)

10 wherein Y, Z, and R' are as defined above,

d) reacting the mixture of (7a) and (7b) with a nucleophile, followed by acidification, to obtain a compound of formula (8a)

wherein Y, Z, and R' are as defined above,

e) reacting a compound of formula (8a) with an acid to obtain THIP as an acid addition salt.

- 20 2. The method of claim 1 wherein step a) is carried out in a polar solvent, such as NMP.
 - 3. The method of any one of claims 1-2, step a), wherein in the alkylating agent of formula (3) R² and R³ are independently selected from H, methyl, ethyl, allyl, phenacyl, phenyl, methoxyphenyl and
- L is selected from Br, Cl, I, OMs, or OTs.

4. The method of claim 3, wherein the alkylating agent of formula (3) is selected from MeI, EtI, BzBr, p-CH₃OC₆H₄CH₂Br, allylBr, and the corresponding mesylates (OMs) and tosylates (OTs).

23

PCT/DK2004/000579

- 5. The method of any one of claims 1-4 wherein the reduction in step b) is carried out in alcohol and water, such as aqueous ethanol.
 - 6. The method of any one of claims 1-5 wherein the mild reducing agent in step b) is LiBH₄ or NaBH₄.
 - 7. The method of any one of claims 1-6, step c), wherein in the reagent of formula (6a) R' is C_{1-12} alkyl, C_{1-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with a C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

X is selected from Cl, Br, I,

15 Y is O, or S

10

20

25

35

Z is O, or S.

WO 2005/023820

- 8. The method of claim 7, step c), wherein the reagent of formula (6a) is selected from C₁₋₁₂alkyl chloroformate, such as methyl chloroformate, ethyl chloroformate, or ethyl chlorothiolformate.
 - 9. The method of claim 1, step c), wherein a compound of formula (5) is first protected as a carbonate or carbamate, such as a *t*-butyl- or 2,2,2-trichloroethylcarbonate/carbamate, and then reacted with the reagent of formula (6a).
 - 10. The method of any one of claims 1-9, step d), wherein the nucleophile is a soft nucleophile, such as aqueous ammonia, an amine or diamine (such as methylamine, ethylenediamine), thiols, thiolates, sulfides, in an aqueous or organic solution.
- 11. The method of any one of claims 1-10, step d), wherein the reaction with a nucleophile is followed by acidification by adjusting pH to ≤ 5 .
 - 12. The method of any one of claims 1-11, wherein step d) after reaction with the nucleophile in an aqueous solution is followed by separating the aqueous phase, followed by acidification with an aqueous acid, and extraction into an organic phase.

- 13. The method of any one of claims 1-12, wherein a compound of formula (8a) or a salt thereof is purified by a process of extraction from one phase to another.
- 14. The method of any one of claims 1-13, wherein a compound of formula (8a) is obtained in high purity, more than 98%, preferably greater than 99% according to HPLC.
 - 15. The method of any one of claims 1-14, wherein step e) is carried out using a mineral acid.
 - 16. A method of preparing a compound of formula (2)

10

comprising reacting the compound of formula (10)

- with a dehydrating agent, to obtain compound of formula (2).
 - 17. A compound of formula (2)

20

25

or a salt thereof.

18. A method of preparing THIP comprising reacting a compound of formula (8a) or a salt thereof

wherein R' is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

Y is O or S, and

Z is O, S or C₁₋₆alkylene,

- 5 with an acid, typically a mineral acid, to obtain THIP as an acid addition salt.
 - 19. A compound of formula (8a)

wherein R' is C₁₋₁₂alkyl, C₁₋₁₂alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, acyl, or aryl

optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

Y is O or S,

Z is O, S or C₁₋₆alkyl, or

a salt thereof.

- 15 20. A method of preparing THIP comprising the steps:
 - a) reacting a compound of formula (2)

with an alkylating agent of formula (3)

20

wherein R^2 and R^3 are independently selected from H, C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, aryl, or heteroaryl, optionally substituted with a C_{1-12} alkyl, C_{1-12} alkoxy, or aryl, and

L is a leaving group, to obtain a quarternary salt of formula (4)

wherein L, R² and R³ are as defined above,

b) reacting the quarternary salt of (4) with a mild reducing agent to obtain a compound of formula (5)

HO
$$N$$
 N
 CH
 R^2
 CH
 R^3
 (5)

wherein R² and R³ are as defined above,

c2) reacting a compound of formula (5) with a reagent of formula (6b)

$$RU$$
=W (6b)

5

10

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U is N or CR¹, wherein R¹ is H, or R,

W is O, S or NR⁴, wherein R⁴ is H, or R,

optionally followed by reaction with a nucleophile,

to obtain a mixture of a compound of formula (7c) and a compound of (7d)

wherein R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U' is N or CR¹, wherein R¹ is H, or R,

W is O, S or NR⁴, wherein R⁴ is H, or R,

20

15

d2) reacting the mixture of (7c) and (7d) with a nucleophile, followed by acidification, to obtain a compound of formula (8b)

wherein W, U', and R are as defined above,

5

- e2) reacting a compound of formula (8b) with an acid to obtain THIP as an acid addition salt.
- 21. The method of claim 20 wherein step a) is carried out in a polar solvent, such as NMP.
- 22. The method of any one of claims 20-21, step a), wherein in the alkylating agent of formula (3) R² and R³ are independently selected from H, methyl, ethyl, allyl, phenacyl, phenyl, methoxyphenyl and L is selected from Br, Cl, I, OMs, or OTs.
- 23. The method of claim 22, wherein the alkylating agent of formula (3) is selected from MeI, EtI, BzBr, *p*-CH₃OC₆H₄CH₂Br, allylBr, and the corresponding mesylates (OMs) and tosylates (OTs).
- 24. The method of any one of claims 20-23 wherein the reduction in step b) is carried out in alcohol and water, such as aqueous ethanol.
 - 25. The method of any one of claims 20-24 wherein the mild reducing agent in step b) is LiBH₄ or NaBH₄.
- 26. The method of any one of claims 20-25, step c2), wherein in the reagent of formula (6b)
 R is C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, acyl, or phenyl optionally substituted with a C₁₋₆alkyl, C₁₋₆alkoxy, or phenyl,
 U is N or CR¹, wherein R¹ is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, acyl, or phenyl optionally substituted with a C₁₋₆alkyl, C₁₋₆alkoxy, or phenyl,
- W is O, S or NR⁴, wherein R⁴ is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or phenyl optionally substituted with a C_{1-6} alkyl, C_{1-6} alkoxy, or phenyl.

27. The method of any one of claims 20-26, step c2), wherein the nucleophile is selected from Cl⁻, Br⁻, I⁻, or NC-S⁻.

28

PCT/DK2004/000579

WO 2005/023820

10

15

25

- 28. The method of any one of claims 26-27, step c2), wherein the reagent of formula (6b) is selected from an isocyanate such as isopropyl isocyanate or phenyl isocyanate, or an isothiocyanate such as phenyl isothiocyanate, or a ketene.
 - 29. The method of claim 20, step c2), wherein a compound of formula (5) is first protected as a carbonate or carbamate, such as a *t*-butyl- or 2,2,2-trichloroethylcarbonate/carbamate, and then reacted with the reagent of formula (6b).
 - 30. The method of any one of claims 20-29, step d2), wherein the nucleophile, is a soft nucleophile, such as aqueous ammonia, an amine or diamine (such as methylamine, ethylenediamine), thiols, thiolates, sulfides, in an aqueous or organic solution.
 - 31. The method of any one of claims 20-30, step d2), wherein the reaction with a nucleophile is followed by acidification by adjusting pH to ≤ 5 .
- 32. The method of any one of claims 20-31, wherein step d2) after reaction with the nucleophile in an aqueous solution is followed by separating the aqueous phase, followed by acidification with an aqueous acid, and extraction into an organic phase.
 - 33. The method of any one of claims 20-32, wherein a compound of formula (8b) or a salt thereof is purified by the process of extraction from one phase to another.
 - 34. The method of any one of claims 20-33, wherein a compound of formula (8b) is obtained in high purity, more than 98%, preferably greater than 99% according to HPLC.
- 35. The method of any one of claims 20-34, wherein step e2) is carried out using a mineral acid.
 - 36. A method of preparing THIP comprising reacting a compound of formula (8b) or a salt thereof

WO 2005/023820

wherein, R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U' is NH or CHR¹, wherein R¹ is H, or R,

W is O, S or NR⁴, wherein R⁴ is H, or R, with an acid, typically a mineral acid, to obtain THIP as an acid addition salt.

37. A compound of formula (8b)

10

wherein, R is C_{1-12} alkyl, C_{2-12} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, acyl, or aryl optionally substituted with one or more C_{1-12} alkyl, C_{1-12} alkoxy, or aryl,

U' is NH or CHR¹, wherein R¹ is H, or R,

W is O, S or NR⁴, wherein R⁴ is H, or R, or

a salt thereof.

INTERNATIONAL SEARCH REPORT

I ----national Application No

. . T/DK2004/000579

A. CLASSII IPC 7	FICATION OF SUBJECT MATTER C07D498/04						
According to	International Patent Classification (IPC) or to both national classifica	ation and IPC					
B. FIELDS	SEARCHED						
Minimum do IPC 7	cumentation searched (classification system followed by classification CO7D	on symbols)					
Documental	ion searched other than minimum documentation to the extent that si	uch documents are included in the fields se	arched				
	ata base consulted during the international search (name of data bas	se and, where practical, search terms used)					
EPO-Internal, CHEM ABS Data							
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT						
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.				
X	EP 0 000 338 A (LUNDBECK & CO AS H) 24 January 1979 (1979-01-24)		18,19, 36,37				
Α	cited in the application Compound Va and its conversion to Ia (page 12)	compound	1,16,17, 20,36,37				
X	DE 31 45 473 A (KEFALAS AS) 26 August 1982 (1982-08-26) example 1		19				
X	DATABASE REGISTRY 'Online! CHEMICAL ABSTRACTS SERVICE, COLUM OHIO, US; XP002308640 retrieved from STN 85118-32-7	IBUS,	19				
Furth	ner documents are listed in the continuation of box C.	χ Patent family members are listed in	annex.				
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published after the or priority date and not in conflict cited to understand the principle invention "X" document of particular relevance; cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document referring to an oral disclosure, use, exhibition or other means "P" document published after the or priority date and not in conflict cited to understand the principle invention "X" document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an inventive step when the document of particular relevance; cannot be considered to involve an involve an inventive step when the document of particular relevance; cannot be considered to involve an invo			with the application but or theory underlying the he claimed invention nnot be considered to e document is taken alone he claimed invention in inventive step when the r more other such docu-ovious to a person skilled				
	actual completion of the international search	Date of mailing of the international sear	ch report				
	December 2004 mailing address of the ISA	16/12/2004 Authorized officer					
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Diederen, J					

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-17,20-35

A method of preparing THIP, intermediate 2 and the process to prepare intermediate 2

2. claims: 18,19,36,37

Compounds of Formula (8a) and (8b) and their use in the synthesis of THIP $\,$

International application No. PCT/DK2004/000579

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. X As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

rnational Application No CT/DK2004/000579

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0000338	Α	24-01-1979	AT	368505 B	25-10-1982
			AT	448678 A	15-02-1982
			AU	3724478 A	03-01-1980
			AU	521040 B2	11-03-1982
			AU	3729878 A	03-01-1980
			CA	1107736 A1	25-08-1981
			CA	1125288 A2	08-06-1982
			DE	2861342 D1	28-01-1982
			DK	270278 A	21-12-1978
			DK	270378 A	21-12-1978
			EP	0000167 A1	10-01-1979
			EP	0000338 A2	24-01-1979
			EP	0027279 A1	22-04-1981
			EP	0028017 A1	06-05-1981
			ES	470912 A1	01-02-1979
			ES	470913 A1	01-02-1979
			FI	781954 A ,B,	21-12-1978
			FI	781955 A	21-12-1978
			ΙE	47200 B1	11-01-1984
			ΙT	1159739 B	04-03-1987
			JP	54036275 A	16-03-1979
			JP	54036290 A	16-03-1979
			NO	782127 A ,B,	21-12-1978
			NO	782128 A	21-12-1978
			NO	792839 A	21-12-1978
			NZ	187615 A	15-12-1981
			US	4301287 A	17-11-1981
			US	4278676 A	14-07-1981
			ZA	7803492 A	27-06-1979
			ZA 	7803493 A	27-06-1979
DE 3145473	Α	26-08-1982	DE	3145473 A1	26-08-1982
			DK	524281 A	28-05-1982
			FR	2494691 A1	28-05-1982
			GB	2088370 A ,B	09-06-1982
			JP	57118584 A	23-07-1982